tradingkey.logo

Bluejay Diagnostics Inc

BJDX

1.487USD

+0.007+0.45%
Market hours ETQuotes delayed by 15 min
823.59KMarket Cap
LossP/E TTM

Bluejay Diagnostics Inc

1.487

+0.007+0.45%
More Details of Bluejay Diagnostics Inc Company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Company Info
Ticker SymbolBJDX
Company nameBluejay Diagnostics Inc
IPO dateNov 10, 2021
CEOMr. Neil (Indranil) Dey
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 10
Address360 Massachusetts Avenue, Suite 203
CityACTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01720
Phone19786310152
Websitehttps://bluejaydx.com/
Ticker SymbolBJDX
IPO dateNov 10, 2021
CEOMr. Neil (Indranil) Dey
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Revenue Breakdown
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
0.47%
L1 Capital Global Opportunities Master Fund Ltd.
0.18%
Tower Research Capital LLC
0.12%
UBS Financial Services, Inc.
0.05%
Lana Management & Business Research International LLC
0.03%
Other
99.15%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
0.47%
L1 Capital Global Opportunities Master Fund Ltd.
0.18%
Tower Research Capital LLC
0.12%
UBS Financial Services, Inc.
0.05%
Lana Management & Business Research International LLC
0.03%
Other
99.15%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.58%
Corporation
0.21%
Investment Advisor
0.05%
Individual Investor
0.04%
Other
99.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
29
13.35K
0.89%
-11.19K
2025Q1
33
13.32K
1.15%
-11.19K
2024Q4
33
13.25K
2.40%
-10.14K
2024Q3
34
31.07K
8.08%
+26.51K
2024Q2
34
7.19K
9.21%
+4.96K
2024Q1
32
2.22K
59.41%
+553.00
2023Q4
32
1.63K
54.54%
+399.00
2023Q3
33
1.19K
46.18%
+12.00
2023Q2
32
1.16K
61.50%
-18.00
2023Q1
29
1.15K
45.43%
-4.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
L1 Capital Global Opportunities Master Fund Ltd.
2.68K
0.18%
+2.68K
--
Jun 27, 2024
Tower Research Capital LLC
1.74K
0.12%
+1.19K
+213.90%
Mar 31, 2025
UBS Financial Services, Inc.
812.00
0.05%
-1.13K
-58.25%
Mar 31, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
Dey (Indranil)
90.00
0.01%
--
--
May 02, 2025
SBI Securities Co., Ltd.
20.00
0%
+20.00
--
Mar 31, 2025
Cook (Jason John)
13.00
0%
--
--
May 02, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Date
Type
Ratio
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jul 21, 2023
Merger
20<1
Jul 21, 2023
Merger
20<1
View more
KeyAI